Premium
Haemophilia prophylaxis: how can we justify the costs?
Author(s) -
FELDMAN B. M.,
BERGER K.,
BOHN R.,
CARCAO M.,
FISCHER K.,
GRINGERI A.,
HOOTS K.,
MANTOVANI L.,
WILLAN A. R.,
SCHRAMM W.
Publication year - 2012
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2012.02790.x
Subject(s) - medicine , haemophilia , haemophilia a , intensive care medicine , quality of life (healthcare) , value (mathematics) , disease , value of life , health care , pediatrics , nursing , economic growth , machine learning , computer science , economics , microeconomics
Summary. Severe haemophilia results in increased mortality and poorer quality of life. Factor prophylaxis leads to a more normal life, but is very costly; most of the cost is due to the high cost of replacement factor. Despite its high cost, factor prophylaxis has been adopted throughout the developed world – even in different health care systems. We argue that there are at least five possible reasons why societies may value factor prophylaxis despite its cost: (i) it is directed towards an inherited disease, (ii) the treatment is largely directed towards children, (iii) the disease is rare and the overall cost to society is small, (iv) the treatment is preventative, and v) the high cost is largely the result of providing safe products. In an era of rising health care costs, there is a strong research agenda to establish the factors that determine the value of expensive therapies for rare diseases like haemophilia.